



(51) International Patent Classification:

C07D 401/14 (2006.01) **A61K 31/454** (2006.01)
C07D 413/14 (2006.01) **A61K 31/4545** (2006.01)
C07D 401/06 (2006.01) **A61K 31/5377** (2006.01)
C07D 403/06 (2006.01) **A61P 27/00** (2006.01)
C07D 417/14 (2006.01) **A61P 37/00** (2006.01)

(21) International Application Number:

PCT/US2014/046515

(22) International Filing Date:

14 July 2014 (14.07.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/846,355 15 July 2013 (15.07.2013) US
 61/977,028 8 April 2014 (08.04.2014) US

(71) Applicant (for all designated States except US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): ADAMS, Christopher [US/US]; Novartis Institutes for BioMedical Research,


Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **CAPPARELLI, Michael Paul** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **EHARA, Takeru** [JP/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, US 02139 (US). **KARKI, Rajeshri Ganesh** [IN/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **MAINOLFI, Nello** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **ZHANG, Chun** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) Common Representative: NOVARTIS AG; Novartis AG, Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,

[Continued on next page]

(54) Title: PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS



(I)

(57) Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.



MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

Published:

— *with international search report (Art. 21(3))*